Norjizak Injection: A Critical Risk for Transmitting Blood-Borne Infectious Diseases

Author Information
Article Notes and Dates
To Cite : Alam Mehrjerdi Z. Norjizak Injection: A Critical Risk for Transmitting Blood-Borne Infectious Diseases, Hepat Mon. 2013 ;13(4):e8272. doi: 10.5812/hepatmon.8272.
Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Footnotes
References
  • 1. Ramezani A, Mohraz M, Gachkar L. Epidemiologic situation of human immunodeficiency virus (HIV/AIDS patients) at a private clinic in Tehran, Iran. Arch Iran Med. 2006; 9(4): 315-8[PubMed]
  • 2. Sharif M, Sherif A, Sayyah M. Frequency of HBV, HCV and HIV infections among hospitalized injecting drug users in Kashan. Indian J Sex Transm Dis. 2009; 30(1): 28-30[DOI][PubMed]
  • 3. Hassannejad R, Kassaian N, Ataei B, Adibi P. High risky behaviors among intravenous drug users in Isfahan, Iran: A study for hepatitis C harm reduction programs. Int J Prev Med. 2012; 3-8[PubMed]
  • 4. Razzaghi EM, Movaghar AR, Green TC, Khoshnood K. Profiles of risk: a qualitative study of injecting drug users in Tehran, Iran. Harm Reduct J. 2006; 3: 12[DOI][PubMed]
  • 5. Mir-Nasseri MM, Mohammadkhani A, Tavakkoli H, Ansari E, Poustchi H. Incarceration is a major risk factor for blood-borne infection among intravenous drug users: Incarceration and blood borne infection among intravenous drug users. Hepat Mon. 2011; 11(1): 19-22[PubMed]
  • 6. Zamani S, Ichikawa S, Nassirimanesh B, Vazirian M, Ichikawa K, Gouya MM, et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy. 2007; 18(5): 359-63[DOI][PubMed]
  • 7. Amin-Esmaeili M, Rahimi-Movaghar A, Razaghi EM, Baghestani AR, Jafari S. Factors correlated with hepatitis c and b virus infections among injecting drug users in Tehran, IR Iran. Hepat Mon. 2012; 12(1): 23-31[DOI][PubMed]
  • 8. Alavi SM, Behdad F. Seroprevalence study of hepatitis C and Hepatitis B virus among hospitalized intravenous drug users in Ahvaz, Iran (2002-2006). Hepat Mon. 2010; 10(2): 101-4[PubMed]
  • 9. Zamani S, Ono-Kihara M, Ichikawa S, Kihara M. Potential for sexual transmission of HIV infection from male injecting-drug users who have sex with men in Tehran, Iran. Sex Transm Dis. 2010; 37(11): 715-8[DOI][PubMed]
  • 10. Siavash M, Janghorbani M, Gheshlaghi F, Adeli SH, Saljoughi M, Moradi F, et al. A case series of abuse of a new opioid combination, Norjizak. J Addict Dis. 2009; 28(2): 180-5[DOI][PubMed]
  • 11. Nemati A. Assessment and follow up of avascular necrosis of femoral head following tamjizak and norjizak in drug abusers [dissertation]. 2007;
  • 12. Shekarchizadeh H, Ekhtiari H, Khami MR, Virtanen JI. Patterns of pre-treatment drug abuse, drug treatment history and characteristics of addicts in methadone maintenance treatment in Iran. Harm Reduct J. 2012; 9(1): 18[DOI][PubMed]
  • 13. Shokuhi S, Nikfarjam Shirazi E, Ali Asgari A, Gachkar L. Prevalence of anergy among hospitalized drug users in southern Tehran. Iran J Clin Infect Dis. 2008; 3(1): 29-33
  • 14. Koushesh HR, Afshari R. A new illicit opioid dependence outbreak, evidence for a combination of opioids and steroids. Drug Chem Toxicol. 2009; 32(2): 114-9[DOI][PubMed]
  • 15. Khorvash F, Fasihi Dastjerdi M, Zarefar S, Jonaidi Jafari N. Infectious complications and mortality due to Norgesic in comparison with other injecting narcotics. Militar Med J. 2006; 8(2): 149-54
  • 16. Tayeri K, Radfar SR, Yaran M, Kassaian N, Nokhodian Z, Ataei B, et al. Isolation of hepatitis C virus in norjizac vials. Hepat Mon. 2010; 10(1): 65-6[PubMed]
  • 17. Farnia M, Ebrahimi B, Shams A, Zamani S. Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran. Int J Drug Policy. 2010; 21(5): 422-4[DOI][PubMed]
  • 18. Razzaghi E, Nassirimanesh B, Afshar P, Ohiri K, Claeson M, Power R. HIV/AIDS harm reduction in Iran. Lancet. 2006; 368(9534): 434-5[DOI][PubMed]
  • 19. Noori R, Narenjiha H, Aghabakhshi H, Habibi G, Khoshkrood Mansoori B. Methadone maintenance therapy outcomes in Iran. Subst Use Misuse. 2012; 47(7): 767-73[DOI][PubMed]
  • 20. Vazirian M, Nassirimanesh B, Zamani S, Ono-Kihara M, Kihara M, Ravari SM, et al. Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: a cross-sectional study. Harm Reduct J. 2005; 2: 19[DOI][PubMed]
  • 21. Zamani S, Vazirian M, Nassirimanesh B, Razzaghi EM, Ono-Kihara M, Mortazavi Ravari S, et al. Needle and syringe sharing practices among injecting drug users in Tehran: a comparison of two neighborhoods, one with and one without a needle and syringe program. AIDS Behav. 2010; 14(4): 885-90[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check